<DOC>
	<DOCNO>NCT02067780</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease ( COPD ) one common diseases world . In recent study , show administration levofloxacin superior placebo treatment decompensation COPD ; accompany substantial reduction mortality significant reduction residence time hospital . In Tunisia , data available epidemiology COPD decompensation . The choice antibiotic use situation challenge clinician must choose traditional antibiotic ( cyclins , aminopenicillins , cotrimoxazole ... ) new antimicrobial agent . Recently , emphasized selection patient treatment accord degree systemic inflammation ( C-Reactive Protein ) . Indeed , would correlation tracheobronchial infection elevate inflammatory marker . As elevation marker proportional intensity inflammatory reaction body , base kinetics biomarkers antibiotic treatment seem logical . Thus , C-Reactive Protein allow know start antibiotic , also kinetic , marker guide duration therapy shorten duration antibiotic therapy : rate cut would ensure antibiotic treatment adopt . The objective randomize prospective double blind study evaluate efficacy safety short treatment 48 levofloxacin compare treatment molecule time guide monitoring marker inflammation patient admitted emergency exacerbation COPD study epidemiology viral bacterial COPD decompensation .</brief_summary>
	<brief_title>Short Antibiotic Treatment Versus Duration Guided Markers Inflammation Treatment AECOPD</brief_title>
	<detailed_description>This study randomize prospective double-blind , accomplish seal envelope , three parallel group : - Group A : Short treatment : 1 tablet Levofloxacin 500mg / day hang two day complete 1 tablet Placebo Levofloxacin 500mg / day 5 day . - Group B : Short Treatment control : 1 tablet Levofloxacin 500mg / day 7 day . - Group C : Titled treatment inflammation marker ( CRP ) : 1 tablet Levofloxacin 500mg / day 7 day . - Group D : Titled treatment inflammation marker ( CRP ) Control : 1 tablet Levofloxacin 500mg / day hang two day complete 1 tablet Placebo Levofloxacin 500mg / day 5 day . We start study recruitment COPD patient collect blood sample sputum sample make control . These sample use inflammatory analysis study bacterial viral serology . The result seize SPSS.18.0 software .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>patient COPD ( accord definition American Thoracic Society ) acute exacerbation Pneumonia Antibiotic treatment previous day Pregnancy Immunodeficiency Concomitant infection intubation immediately</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>